Member login

Forgot Password?
Return to login
Back to News index

Reaction to the EU Referendum result

 

Warwick Smith, Director General of the British Generic Manufacturers Association and the British Biosimilars Association, said: “

“The existence of a single European marketing authorisation for medicines has generated considerable benefits for patients, the NHS and the industry. The single European marketing authorisation reduces cost and complexity for manufacturers, facilitating the production and regulation of high quality medicines and their availability to patients. 

“The UK generic and biosimilar medicines industry therefore urges the Government to do everything possible to maintain this European marketing authorisation system in the forthcoming negotiations with the European Union.”